CMS Vagus Nerve Stimulation Coverage Policy Update (NCD 230): What Billing Teams Need to Know in 2026

The Centers for Medicare & Medicaid Services has modified its National Coverage Determination for Vagus Nerve Stimulation (NCD 230), with an effective date of March 12, 2026. This update refines coverage parameters for VNS devices across two established indications—medically refractory partial onset seizures and treatment resistant depression (TRD)—and billing teams serving neurology, psychiatry, and surgical practices need to understand exactly what criteria must be met before submitting claims.

What Is Vagus Nerve Stimulation and How Does CMS Classify It?

VNS is a surgically implanted pulse generator—functionally similar to a cardiac pacemaker—placed under the skin of the left chest. An electrical lead connects the generator to the left vagus nerve, which transmits signals to the brain. The FDA approved VNS for refractory epilepsy in 1997 and for treatment resistant depression in 2005.

Under NCD 230, CMS classifies VNS under multiple benefit categories: Durable Medical Equipment (DME), Incident to a Physician's Professional Service, and Physicians' Services. That multi-category classification matters for billing—claims may route differently depending on the site of service, the implanting provider's relationship to the beneficiary's care, and how the DME component is billed separately from the surgical procedure.

CMS Coverage Criteria for VNS: Epilepsy Indication

For patients with epilepsy, CMS coverage has been in place since July 1, 1999, and the updated NCD 230 maintains that framework. VNS is covered as reasonable and necessary when both of the following are true:

This is a relatively clean coverage pathway compared to the TRD indication. Medical necessity documentation should clearly establish the refractory nature of the seizure disorder and include documentation of why surgical intervention is not an option—or a record of prior failed surgical treatment. Gaps in that documentation are the most common reason these claims face scrutiny on audit.

CMS Coverage for Treatment Resistant Depression: Coverage with Evidence Development

The TRD pathway under NCD 230 is substantially more complex. Effective February 15, 2019, CMS covers FDA-approved VNS devices for TRD only through Coverage with Evidence Development (CED)—meaning coverage is tied to participation in a CMS-approved clinical trial, not standard clinical care.

This is not open-ended coverage. To be billable under this CED pathway, the VNS must be provided within a CMS-approved, double-blind, randomized, placebo-controlled trial with a minimum follow-up duration of at least one year. CMS also allows the possibility of extending the study to a prospective longitudinal study once the controlled trial has completed enrollment, provided there are positive interim findings.

Billing outside of an approved trial protocol for the TRD indication will not meet medical necessity under NCD 230—full stop.

Patient Eligibility Criteria for TRD Coverage

CMS specifies strict patient-level criteria that must be documented in the medical record. All of the following must be present:

• The patient is in a major depressive disorder (MDD) episode for ≥ two years, OR has had at least four MDD episodes, including the current one
• Diagnosis must be confirmed using the most current DSM edition and a structured clinical assessment
• The patient's depressive illness meets a minimum of four prior failed treatments of adequate dose and duration, as measured by a validated assessment tool
• The patient must currently be experiencing a major depressive episode (note: the source document was truncated at this point, and additional criteria may apply—see the full NCD 230 text at the CMS source)

These are not soft criteria. Each element requires specific, contemporaneous documentation. A billing team that submits a TRD VNS claim without verifying that all criteria are charted is exposing the practice to denial and potential recoupment.

Research Questions That Must Be Addressed in Approved Trials

CMS requires that each approved study protocol address nine specific research questions, analyzed separately for patients with bipolar versus unipolar disease. These include:

• Rate of response (defined as ≥ 50% improvement in depressive symptoms from baseline on a guideline-recommended depression scale)
• Rate of remission (defined as falling below threshold on a guideline-recommended depression scale)
• Time from treatment until response and remission are first achieved
• Population distributions of maximum months of response and remission—both consecutive and overall
• Patient variables associated with successful VNS treatment for TRD
• Observed harms
• Changes in disability, quality of life, general psychiatric status, and suicidality

While billing teams won't typically be answering these questions directly, the protocol requirements confirm that CED coverage is not a workaround for standard coverage—it is a research framework with strict documentation obligations attached to every enrolled patient.

Affected Codes

This policy does not list specific CPT, HCPCS, or ICD-10 codes in the available policy data for NCD 230. Billing teams should consult the full NCD 230 text directly at CMS.gov and cross-reference with their internal code mapping for VNS implantation, DME billing for the pulse generator, and any applicable ICD-10 diagnosis codes for refractory epilepsy or major depressive disorder. Your MAC (Medicare Administrative Contractor) may also have jurisdiction-specific LCDs that map codes to this NCD.

What Your Billing Team Should Do